orphan drugs

Catalyst Pharmaceuticals trades at 20-33% discount to peers with 7.5% FCF yield; 2026 Hetero litigation is binary catalyst determining if shares reach $28-32 or collapse to $16-20.

Lamzede market expands globally, led by Europe with fastest growth in Asia-Pacific, driven by rare disease diagnostic advances and enzyme replacement therapy adoption.